Canine osteosarcoma: amputation and chemoimmunotherapy.

[1]  D. Knapp,et al.  Amputation and carboplatin for treatment of dogs with osteosarcoma: 48 cases (1991 to 1993). , 1996, Journal of veterinary internal medicine.

[2]  W. Rand,et al.  Results of surgery and doxorubicin chemotherapy in dogs with osteosarcoma. , 1995, Journal of the American Veterinary Medical Association.

[3]  E. Kleinerman,et al.  Efficacy of Liposomal Muramyl Tripeptide (CGP 19835A) in the Treatment of Relapsed Osteosarcoma , 1995, American journal of clinical oncology.

[4]  C. Rodriguez,et al.  Current studies of liposome muramyl tripeptide (CGP 19835A lipid) therapy for metastasis in spontaneous tumors: a progress review. , 1994, Journal of drug targeting.

[5]  P. Furmanski,et al.  Analysis of the antimetastatic effects of synthetic muramyl tripeptide (CGP 19835A) encapsulated in liposomes in combination with other immunomodulatory agents and chemotherapeutic drugs. , 1993, In vivo.

[6]  E. Macewen,et al.  In vitro and in vivo canine mononuclear cell production of tumor necrosis factor induced by muramyl peptides and lipopolysaccharide. , 1993, Veterinary immunology and immunopathology.

[7]  E. Macewen,et al.  In vitro and in vivo effect of doxorubicin combined with liposome-encapsulated muramyl tripeptide on canine monocyte activation. , 1993, Cancer research.

[8]  C. Czuprynski,et al.  Muramyl peptides augment the in vitro and in vivo cytostatic activity of canine plastic-adherent mononuclear cells against canine osteosarcoma cells. , 1993, Cancer biotherapy.

[9]  G. Fleuren,et al.  Tumor infiltrating cells in human cancer. On the possible role of CD16+ macrophages in antitumor cytotoxicity. , 1992, Laboratory investigation; a journal of technical methods and pathology.

[10]  E. Kleinerman,et al.  Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  N. Nagata,et al.  Serial changes of the serum macrophage colony-stimulating factor level after cytoreductive chemotherapy. , 1992, International journal of hematology.

[12]  J. P. Thompson,et al.  Evaluation of survival times after limb amputation, with and without subsequent administration of cisplatin, for treatment of appendicular osteosarcoma in dogs: 30 cases (1979-1990). , 1992, Journal of the American Veterinary Medical Association.

[13]  B. Powers,et al.  Comparative aspects of osteosarcoma. Dog versus man. , 1991, Clinical orthopaedics and related research.

[14]  G. Ogilvie,et al.  Amputation and cisplatin for treatment of canine osteosarcoma. , 1991, Journal of veterinary internal medicine.

[15]  E. Kleinerman,et al.  Muramyl tripeptide phosphatidylethanolamine encapsulated in liposomes stimulates monocyte production of tumor necrosis factor and interleukin-1 in vitro. , 1991, Cancer communications.

[16]  B. Passlick,et al.  Identification and characterization of a novel monocyte subpopulation in human peripheral blood. , 1989, Blood.

[17]  P. Manley,et al.  Therapy for osteosarcoma in dogs with intravenous injection of liposome-encapsulated muramyl tripeptide. , 1989, Journal of the National Cancer Institute.

[18]  I. Fidler,et al.  Recognition and destruction of neoplastic cells by activated macrophages: discrimination of altered self. , 1988, Biochimica et biophysica acta.

[19]  Withrow Sj,et al.  Canine osteosarcoma. Treatment by amputation versus amputation and adjuvant chemotherapy using doxorubicin and cisplatin. , 1988 .

[20]  I. Fidler,et al.  The biology of cancer metastasis and implications for therapy. , 1987, Current problems in surgery.

[21]  I. Fidler,et al.  Synergistic activation by recombinant mouse interferon-gamma and muramyl dipeptide of tumoricidal properties in mouse macrophages. , 1985, Journal of immunology.

[22]  I. Fidler,et al.  Lymphokine-activated human blood monocytes destroy tumor cells but not normal cells under cocultivation conditions. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  I. Fidler,et al.  Tumoricidal activity of human monocytes activated in vitro by free and liposome-encapsulated human lymphokines. , 1983, The Journal of clinical investigation.

[24]  I. Fidler,et al.  Systemic Activation of Macrophages and Treatment of Cancer Metastases by Liposomes containing Hydrophilic or Lipophilic Muramyl Dipeptide , 1983 .

[25]  E. Macewen,et al.  Canine osteogenic sarcoma treated by amputation and MER: An adverse effect of splenectomy on survival , 1982, Cancer.

[26]  I. Fidler,et al.  Involvement of macrophages in the eradication of established metastases following intravenous injection of liposomes containing macrophage activators. , 1982, Cancer research.

[27]  D. Golde,et al.  The Pulmonary-Alveolar Macrophage , 1979 .

[28]  Brodey Rs.  The use of naturally occurring cancer in domestic animals for research into human cancer: general considerations and a review of canine skeletal osteosarcoma. , 1979 .

[29]  D. Golde,et al.  Direct evidence for a bone marrow origin of the alveolar macrophage in man. , 1976, Science.

[30]  D. Bostock,et al.  Studies on chemotherapy and immunotherapy in canine lymphosarcoma and osteosarcoma. , 1975, Bibliotheca haematologica.

[31]  J. Hibbs.  Discrimination between neoplastic and non-neoplastic cells in vitro by activated macrophages. , 1974, Journal of the National Cancer Institute.